Arch Biopartners (OTCPK:ACHF.F) - Stock Price, News & Analysis

ACHF.F Stock Overview

Arch Biopartners Inc., junto con sus filiales, se dedica al desarrollo de fármacos terapéuticos para la inflamación y las lesiones agudas de órganos en Canadá.

About the company

ACHF.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Los beneficios han crecido 5.3% al año en los últimos 5 años.

Risk Analysis

Fondos propios negativos

Tiene menos de 1 año de cash runway

No tiene ingresos significativos (CA$2M)

Arch Biopartners Inc. Competitors

Alpha Teknova

NasdaqGM:TKNO

US$104.7m

PhenomeX

NasdaqGS:CELL

US$99.6m

Bioqual

OTCPK:BIOQ

US$71.6m

Harvard Bioscience

NasdaqGM:HBIO

US$196.3m

Price History & Performance

Summary of all time highs, changes and price drops for Arch Biopartners
Historical stock prices
Current Share Price	US$1.77
52 Week High	US$1.88
52 Week Low	US$0.72
Beta	1.34
1 Month Change	37.74%
3 Month Change	66.98%
1 Year Change	10.63%
3 Year Change	62.39%
5 Year Change	108.24%
Change since IPO	149.30%

Recent updates

Shareholder Returns

	ACHF.F	US Life Sciences	US Market
7D	0%	-1.1%	-0.7%
1Y	10.6%	0.6%	25.9%

Rentabilidad frente al sector: ACHF.F superó al sector US Life Sciences , que obtuvo un rendimiento del 1.7% el año pasado.

Rentabilidad vs. Mercado: ACHF.F obtuvo unos resultados inferiores a los del mercado US, que fue del 15.2% el año pasado.

Price Volatility

Is ACHF.F's price volatile compared to industry and market?
ACHF.F volatility
ACHF.F Average Weekly Movement	7.6%
Life Sciences Industry Average Movement	7.2%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ACHF.Fha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ACHF.F (10%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Richard Muruve	https://www.archbiopartners.com

Arch Biopartners Inc., junto con sus filiales, se dedica al desarrollo de fármacos terapéuticos para la inflamación y las lesiones agudas de órganos en Canadá. Se centra en el desarrollo de su principal candidato a fármaco, el péptido LSALT, un producto en fase 2 de ensayos clínicos para tratar la inflamación de órganos mediada por la dipeptidasa-1 en pulmones, hígado y riñones. La empresa también desarrolla AB569 para el tratamiento de infecciones bacterianas resistentes a los antibióticos y para el tratamiento de heridas; y Borg, una interfaz péptido-superficie sólida para reducir la corrosión de los metales.

Arch Biopartners Inc. Fundamentals Summary

How do Arch Biopartners's earnings and revenue compare to its market cap?
ACHF.F fundamental statistics
Market cap	US$109.82m
Earnings (TTM)	-US$1.44m
Revenue (TTM)	US$1.36m

81.7x

P/S Ratio

-77.3x

P/E Ratio

Is ACHF.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACHF.F income statement (TTM)
Revenue	CA$1.85m
Cost of Revenue	CA$1.81m
Gross Profit	CA$32.20k
Other Expenses	CA$1.98m
Earnings	-CA$1.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	1.74%
Net Profit Margin	-105.69%
Debt/Equity Ratio	-88.2%

How did ACHF.F perform over the long term?

See historical performance and comparison

ACHF.F Stock Overview

Rewards

Risk Analysis

Arch Biopartners Inc. Competitors

NasdaqGM:TKNO

US$104.7m

NasdaqGS:CELL

US$99.6m

OTCPK:BIOQ

US$71.6m

NasdaqGM:HBIO

US$196.3m

Price History & Performance

Recent News & Updates

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Recent updates

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide